Form 4: Iovance Biotherapeutics Director Wendy L. Yarno Acquires 25,000 Deferred Restricted Stock Units

Director Wendy L. Yarno acquired 25,000 deferred restricted stock units in Iovance Biotherapeutics, Inc. on March 1, 2024.

Summary

• On March 1, 2024, Wendy L. Yarno, a director of Iovance Biotherapeutics, Inc., acquired 25,000 deferred restricted stock units (DRSUs).
• These DRSUs represent a contingent right to receive one share of Iovance's common stock each.
• The grant was made pursuant to the Issuer's 2018 Equity Incentive Plan (as amended).
• 50% of the RSUs will vest on the 6-month anniversary of the date of grant and the remaining RSUs will vest on the one-year anniversary of the date of grant.
• The issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date.
• Following the transaction, Ms. Yarno beneficially owns 25,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock units by a director is generally a positive sign, indicating confidence in the company's future. However, it's a routine transaction and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of deferred restricted stock units by a director signals confidence in the company's future performance.

Future Outlook

The deferred nature of the stock units suggests a long-term alignment of the director's interests with the company's performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The acquisition of stock units by a director can positively influence shareholder confidence.

Key Dates